Banaras Hindu University team has been granted permission to apply for a German patent by the German Patent and Trademark Office (DPMA) for research on SARS CoV-2 virus.
Rahul Palleti | May 31, 2023 | 07:14 PM IST
NEW DELHI: The German Patent and Trade Mark Office (DPMA) has granted permission for a German patent to Parimal Das and his team at Banaras Hindu University (BHU) who have developed a system to inhibit the growth of the SARS-CoV-2 virus using the Somnifericin Phyto molecule to mark a major advancement in the fight against the virus.
"Phytomolecules such as Somnifericin may be effective in combating the SARS CoV-2 virus, as it inhibits the growth of target cells. This virus poses a global threat to public health. This breakthrough development aims to provide a novel approach to containing the virus's growth and proliferation, potentially leading to improved treatment options and preventative measures," said Das, Coordinator, Centre for Genetic Disorders,
The discovery opened up new possibilities for antiviral therapies and preventative measures. The research team is seeking collaborations to accelerate development and deployment of the system.
Also Read | Sci-Hub & Open Sources: Faizuddin Ahmed joined Stanford’s list of top scientists while teaching in school
"With the German patent, we are dedicated to finding innovative solutions in order to combat the SARS CoV-2 virus. The Somnifericin Phytomolecule growth inhibitor has the potential to play a significant role in the ongoing fight against this global pandemic." said Das.
The German patent symbolises progress and dedication for researcher’s collective efforts. The team behind the Somnifericin Phyto molecule growth inhibitor remains committed to advancing their research. They are also committed to making an impact in the fight against this global health crisis.
Follow us for the latest education news on colleges and universities, admission, courses, exams, research, education policies, study abroad and more..
To get in touch, write to us at news@careers360.com.